COL4A5 and X-linked hydrocephalus with stenosis of the aqueduct of Sylvius: In XLAS, ASO therapy targeting exon 21 in COL4A5 significantly improved the clinical phenotypes of a mouse model of AS, suggesting that exon skipping may represent a promising therapeutic approach for treating severe male XLAS cases [35].